Presidential Executive Order Focuses On Psychedelic Medication; FDA Announces Shortened Review Process

In an executive order issued on April 18, 2026, President Trump signaled that the administration would focus on identifying and approving different types of medications to treat serious mental illness (SMI), and the order, Accelerating Medical Treatments For Serious Mental Illness, specifically supported development of medications based on psychedelic compounds. A week later, the U.S. Food and Drug Administration (FDA) announced it had selected three psychedelic medications for SMI in development for a new priority voucher program that could reduce drug review timelines to as little as one to two months.

The vouchers apply to treatments that have already . . .